Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-6bf8c574d5-mggfc Total loading time: 0 Render date: 2025-02-23T06:38:56.095Z Has data issue: false hasContentIssue false

Droxidopa

Published online by Cambridge University Press:  20 February 2025

K. Ray Chaudhuri ,
Peter Jenner ,
Valentina Leta ,
Shelley Jones  and
Iro Boura
K. Ray Chaudhuri
Affiliation:
King's College London
Peter Jenner
Affiliation:
King's College London
Valentina Leta
Affiliation:
King's College London
Shelley Jones
Affiliation:
King's College London
Iro Boura
Affiliation:
St. George General Hospital of Chania, Crete, Greece
Get access

Summary

Droxidopa ( (–)-threo-3-(3,4-dihydroxyphenyl)-l-serine) is an odourless, tasteless, white to off-white crystalline powder, which is slightly soluble to water. It has a molecular weight of 213.2 and a molecular formula of C9H11NO5.

Type
Chapter
Information
The Movement Disorders Prescriber's Guide to Parkinson's Disease , pp. 137 - 145
Publisher: Cambridge University Press
Print publication year: 2025

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Suggested Reading

Elgebaly, A, Abdelazeim, B, Mattar, O, Gadelkarim, M, Salah, R, Negida, A. Meta-analysis of the safety and efficacy of droxidopa for neurogenic orthostatic hypotension. Clin Auton Res 2016; 26(3): 171–180.CrossRefGoogle ScholarPubMed
Hauser, RA, Isaacson, S, Lisk, JP, Hewitt, LA, Rowse, G. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson’s disease (nOH306B). Mov Disord 2015; 30(5): 646–554.CrossRefGoogle ScholarPubMed
Kaufmann, H, Freeman, R, Biaggioni, I, Low, P, Pedder, S, Hewitt, A, Mathias, C. Treatment of neurogenic orthostatic hypotension with droxidopa: results from a multi-center, double-blind, randomized, placebo-controlled, parallel group, induction design study (PL02.001). Neurology 2012; 78(1 Supplement): PL02.001.CrossRefGoogle Scholar
Zhao, S, Cheng, R, Zheng, J, Li, Q, Wang, J, Fan, W, Zhang, L, Zhang, Y, Li, H, Liu, S. A randomized, double-blind, controlled trial of add-on therapy in moderate-to-severe Parkinson’s disease. Parkinsonism Relat Disord 2015; 21(10): 1214–1218.CrossRefGoogle ScholarPubMed

References

AHFS Drug information, 2012. Bethesda: American Society of Health-System Pharmacists. Accessed on 12 December 2022 via www.medicinescomplete.com.Google Scholar
Biaggioni, I, Freeman, R, Mathias, CJ, Low, P, Hewitt, LA, Kaufmann, H. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Hypertension 2015; 65(1): 101–107.CrossRefGoogle ScholarPubMed
Droxidopa. In: Brayfield, A (Ed.), Martindale: The Complete Drug Reference. London: The Royal Pharmaceutical Society of Great Britain. Accessed on 12 December via www.medicinescomplete.com.Google Scholar
Droxidopa. In: DRUGDEX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Accessed on 12 December via www.micromedexsolutions.com.Google Scholar
Fukada, K, Endo, T, Yokoe, M, Hamasaki, T, Hazama, T, Sakoda, S. L-threo-3,4-dihydroxyphenylserine (L-DOPS) co-administered with entacapone improves freezing of gait in Parkinson’s disease. Med Hypotheses 2013; 80(2): 209–212.CrossRefGoogle ScholarPubMed
Isaacson, S, Vernino, S, Ziemann, A, Rowse, GJ, Kalu, U, White, WB. Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension. J Am Soc Hypertens 2016; 10(10): 755–762.CrossRefGoogle ScholarPubMed
Kaufmann, H, Norcliffe-Kaufmann, L, Palma, JA. Droxidopa in neurogenic orthostatic hypotension. Expert Rev Cardiovasc Ther 2015; 13(8): 875–991.CrossRefGoogle ScholarPubMed
Matsuo, H, Takashima, H, Kishikawa, M, Kinoshita, I, Mori, M, Tsujihata, M, Nagataki, S. Pure akinesia: an atypical manifestation of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1991; 54(5): 397–400.CrossRefGoogle ScholarPubMed
Ogawa, N, Yamamoto, M, Takayama, H. L-threo-3, 4-dihydroxyphenylserine treatment of Parkinson’s disease. J Med 1985; 16(5–6): 525–534.Google Scholar
Ray Chaudhuri, K, Leta, V, Bannister, K, Brooks, DJ, Svenningsson, P. The noradrenergic subtype of Parkinson disease: from animal models to clinical practice. Nat Rev Neurol 2023; 19: 333–345.CrossRefGoogle Scholar
Tohgi, H, Abe, T, Takahashi, S. The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients. J Neural Transm Park Dis Dement Sect 1993: 5(1): 27–34.CrossRefGoogle ScholarPubMed
Yoshida, M, Noguchi, S, Kuramoto, S.. L-threo-3,4-dihydroxyphenylserine treatment for gait apraxia in parkinsonian patients. Kurume Med J 1989; 36(2): 67–74.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Droxidopa
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.015
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Droxidopa
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.015
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Droxidopa
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.015
Available formats
×